First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

计划入组 96 人 · 首次发布于 2010 年 5 月 11 日

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

首次发布于 2014 年 4 月 16 日

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

计划入组 46 人 · 首次发布于 2011 年 5 月 25 日

anti-CXCR4 humanized antibodies

Anti-CXCR4 monoclonal antibodies(Northwest Biotherapeutics)

Anti-CXCR4 mRNA vaccine (Massachusetts General Hospital)

Novel Anti-Infective Technologies, LLC

AiCuris Anti-Infective Cures AG

Germany

AGENCE REGIONALE DE SANTE DE LA REUNION

Reunion

Anti-CXCR4 and Anti-PD-1 Combination Shows Promise in Liver Cancer Treatment

CXCR4 Engineering Transforms CAR-T Cell Therapy: Enhanced Memory Formation and Durable Anti-Leukemic Immunity

Pentixapharm's CXCR4-Targeted Radiopharmaceuticals Show Promise in Primary Aldosteronism and Bladder Cancer